Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Slides:

Advertisements

Similar presentations

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

Advertisements

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Quantification of emphysema with preoperative computed tomography has stronger association with pulmonary complications than pulmonary function test results.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis Hyun Lee, MD,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and βIII-Tubulin Between.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure Jessamy A. Boyd, MD, Jessica L. Hubbs,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma So Hee Song, MD, Hyunjin Park, PhD, Geewon Lee, MD,

Frank Detterbeck, MD Journal of Thoracic Oncology

Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer Se Hoon Choi, MD, Young Tae Kim, MD, PhD,

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer Jeong-Ok Lee, MD, Tae Min.

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation Bhumsuk.

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

PET/CT Findings for Bone Marrow Carcinosis Because of Lung Adenocarcinoma Keisuke Watanabe, MD, Masaharu Shinkai, MD, PhD, Kenjiro Nagai, MD, Nobuhiro.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Analysis of Tumor Markers in the Cytological Fluid Obtained from Computed Tomography-Guided Needle Aspiration Biopsy for the Diagnosis of Non-small Cell.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Histological Subtypes of Lung Adenocarcinoma Have Differential 18F- Fluorodeoxyglucose Uptakes on the Positron Emission Tomography/Computed Tomography.

Nicholas Trakul, MD, PhD, Jeremy P

Nicholas W. Choong, MD, Robert S. Hellman, MD

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Comparison of Neoadjuvant Chemotherapy Followed by Surgery to Upfront Surgery for Thymic Malignancy Samina Park, MD, In Kyu Park, MD, PhD, Young Tae.

Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer Yoon Hee Choi, MD,

Marianna Koczywas, MD, Mihaela C. Cristea, MD

European Lung Cancer Conference (ELCC) 2016 Organisation

Metastatic Lung Cancer to the Pancreas

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

Journal of Thoracic Oncology

Role of Positron Emission Tomography/Computed Tomography Findings for Adjuvant Chemotherapy Indications in Stage T1b-2aN0M0 Lung Adenocarcinoma Shinsuke.

Long-Term Follow-Up of Ground-Glass Nodules After 5 Years of Stability

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-small Cell Lung Cancer Joon Suk Park, MD, Hee Chul Yang, MD, Hong Kwan Kim, MD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer Ho Yun Lee, MD, Hyun Ju Lee, MD, Young Tae Kim, MD, Chang Hyun Kang, MD, Bo Gun Jang, MD, Doo Hyun Chung, MD, Jin Mo Goo, MD, Chang Min Park, MD, Chang Hyun Lee, MD, Keon Wook Kang, MD Journal of Thoracic Oncology Volume 5, Issue 4, Pages 497-503 (April 2010) DOI: 10.1097/JTO.0b013e3181d2efe7 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Time to recurrence (TTR) based on tumor response on computed tomography (CT). Comparing patients with and without radiologic responses (≥30% reduction of tumor size), there was no significant difference in the TTR between the two groups (mean TTR, 44.7 versus 24.5 months and median TTR, not reached versus 16.8 months, respectively; p = 0.11). Journal of Thoracic Oncology 2010 5, 497-503DOI: (10.1097/JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Time to recurrence (TTR) based on tumor response by positron emission tomography/computed tomography (PET/CT, ≥25% reduction of SUVmax). Comparing patients with and without responses, there was no significant difference in the TTR between the two groups (mean TTR, 42.1 versus 23.9 months and median TTR, not reached versus 18.2 months, respectively; p = 0.19). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, 497-503DOI: (10.1097/JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Time to recurrence (TTR) based on tumor response by positron emission tomography/computed tomography (PET/CT, ≥50% reduction of SUVmax). Patients with a metabolic response of ≥50% reduction of SUVmax had a longer TTR than patients without response (mean TTR, 51.7 versus 22.7 months and median TTR, not reached versus 18.2 months, respectively; p = 0.005). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, 497-503DOI: (10.1097/JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Time to recurrence (TTR) based on radiologic-metabolic tumor response (≥30% reduction of tumor size and ≥25% reduction of SUVmax). Radiologic-metabolic responders had a longer TTR than patients with radiologic-metabolic nonresponse, radiologic response only, and metabolic response only (mean TTR, 49.4 versus 23.5 months and median TTR not reached versus 16.8 months, respectively; p = 0.022). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, 497-503DOI: (10.1097/JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Time to recurrence (TTR) based on radiologic-metabolic tumor response (≥30% reduction of tumor size as well as ≥50% reduction of SUVmax). Radiologic-metabolic responders had a longer TTR than patients with radiologic-metabolic nonresponse, radiologic response only, and metabolic response only (mean TTR, 58.7 months versus 22.3 months and median TTR, not reached versus 16.8 months, respectively; p = 0.001). SUVmax, maximum standardized uptake value. Journal of Thoracic Oncology 2010 5, 497-503DOI: (10.1097/JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Time to recurrence (TTR) based on pathologic response. Patients with a pathologic response of ≤10% of viable tumor cells had a longer TTR than patients without response (mean TTR, 44.2 months versus 31.7 months and median TTR, not reached versus 23.1 months, respectively; p = 0.015). Journal of Thoracic Oncology 2010 5, 497-503DOI: (10.1097/JTO.0b013e3181d2efe7) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions